Background
According to the World Health Organization (WHO), colorectal cancer (CRC) is the third most common cancer in males and the second in females and is the fourth cause of cancer death. The WHO expects an increase in CRC incidence and mortality, with estimates of around 1,471,808 newly diagnosed patients and 726,028 deaths worldwide in 2015 [
1]. Almost all (95%) of these new CRCs are likely to be adenocarcinomas and, despite recent advances in detection and therapy, 25% of these patients will develop metastasis and have a very low 5-year survival rate of around 10% [
2,
3]. New biomarkers of CRC are needed to permit an earlier diagnosis and to predict the response to treatment.
Screening for the early detection of CRC is the most effective approach against this disease [
4]. Carcinoembryonic antigen (CEA) is recommended as a biomarker to detect spread of the cancer and to follow up CRC patients. However, in the diagnosis of early CRC it has major limitations such as low sensitivity and specificity (36% and 87% respectively). In addition, until a rate of 16% may be false positives [
5,
6]. Novel biomarkers such as O
6-methylguanine-DNA methyltransferase (MGMT) and CD133 have been proposed as useful tools for the diagnosis, prognosis, and follow-up of CRC and for the detection of relapse [
7]. MGMT is a DNA repair protein that removes O
6-guanine adducts from DNA [
8]. MGMT restores mutagenic O
6-methylguanine to guanine in normal colonic tissue, preventing DNA alkylation damage [
9]. MGMT hypermethylation in CpG islands and low MGMT protein expression appear to be early events in CRC patients. This MGMT epigenetic silencing may lead to G:C to A:T transition mutations in
p53 [
10],
K-ras [
11‐
13],
PIK3CA [
11,
14], and
hMLH1 [
15], among others. Furthermore, CD133, a transmembrane glycoprotein related to cell-cell interaction and signal transduction, has been associated with cancer stem cells (CSCs), including those in CRC [
16]. This CSC subpopulation represents a small number of tumor cells that can self-renew indefinitely and recreate parent tumor cells expressing different surface biomarkers [
17]. This marker permits the hierarchical organization of tumor heterogeneity, dividing CRC cells between CD133-positive (CSCs) and CD133-negative cells (non-CSCs) cells [
18]. CD133-positive CRC cells have shown special properties, including the capacity to form tumors in xenografts [
19], chemo- and radioresistance [
20,
21], and metastasis promotion [
22,
23]. Previous studies associated CSC chemo/radio-resistance to MGMT expression in other cancers [
24‐
26].
The aim of the present study was to analyze the clinical implications of MGMT and CD133 in CRC and the possible interactions between them in order to develop a new prognostic biomarker for these patients. Immunohistochemical analysis of MGMT and CD133 expression was carried out in colorectal cancer samples from 123 patients, and MGMT methylation status was determined by methylation-specific PCR (MSP). The expression pattern of the two molecules and MGMT methylation status were correlated with overall survival (OS), disease-free survival (DFS), tumor stage, and differentiation grade, among others. MGMT expression intensity and percentage CD133 expression may be clinically useful for CRC prognosis, but this does not appear to be the case for MGMT methylation status or CD133 expression intensity.
Discussion
In this study of tumors from CRC patients, methylated MGMT promoter was significantly associated with low MGMT expression intensity and poor-differentiation grade but not with OS, DFS, or tumor stage. High MGMT expression intensity was correlated with longer OS but not with DFS, tumor stage, or differentiation grade. High percentage of CD133 expression was correlated with shorter DFS but not with OS, tumor stage, or differentiation grade. MGMT expression intensity can be considered as an independent prognostic factor for OS, but the influence of percentage CD133 expression on the prognosis for DFS also depends on the tumor stage.
The relevance of MGMT in CRC carcinogenesis is widely accepted, and reduced MGMT expression has been documented in tumor
versus normal colon tissue [
30]; however, the mechanism by which MGMT expression is controlled remains controversial. Lee
et al. [
31] observed hypermethylated genes, including MGMT, in early stages of colorectal adenoma, and MGMT promoter methylation has been implicated in colon cancer progression (in the adenoma-carcinoma sequence) [
31,
32]. Sinha
et al. [
33] demonstrated that MGMT promoter methylation was associated with tumor stage, metastasis, and lymphatic invasion in advanced CRC. Various authors have reported the effects of MGMT inactivation on other cancer-related genes. It has been found that the epigenetic silencing of MGMT by promoter hypermethylation can lead to G:C to A:T transition mutations in
p53 [
10],
K-ras [
11‐
13], and
PIK3CA [
11,
14], facilitating progression of the tumor to more advanced stages.
Based on the above data, research efforts have focused on the diagnostic and prognostic relevance of MGMT. Various authors have reported that MGMT methylation is a useful marker to detect early stages of CRC [
34,
35]. Kang
et al. [
36] concluded that a more sensitive screening can be achieved by testing the DNA methylation status of some genes, including MGMT, than by analyzing fecal blood. In addition, Nagasaka
et al. [
37] and Nilsson
et al. [
38] suggested that MGMT hypermethylation in CRC may be related to non-recurrence after chemotherapy and better survival. Experimental data support this possibility, because 5-FU cytotoxicity was enhanced by O6-benzylguanine-induced MGMT depletion in colon cancer cells with high MGMT expression. It was suggested that elevated MGMT levels may be a marker of a low therapeutic response [
39], and MGMT hypermethylation was associated with a better prognosis in CRC patients [
38]. In contrast, Shima
et al. [
11] found no significant correlation between MGMT promoter status and survival and suggested that this status has little clinical relevance. Our results showed a significant association of methylated MGMT promoter with low-MGMT expression intensity and poor-differentiation grade. However, no correlation was found between MGMT methylation and OS or DFS in CRC patients, whereas high MGMT intensity was correlated with longer OS but not with tumor grade or differentiation. These contradictory results may be related to the multifactorial and complex regulation of MGMT protein expression. Two distinct patterns of MGMT methylation have been associated with different mutations or epigenetic changes in CRC [
40], and methylation is not the sole regulatory mechanism of MGMT protein levels [
41]. Some MGMT polymorphisms may reduce MGMT activity and/or sensitivity [
42,
43] and have been associated with progression-free survival in CRC patients [
44]. Despite MGMT hypermethylation or lack of MGMT protein has been associated with a better treatment response and survival at short-term [
37‐
39], the epigenetic silencing of MGMT promotes different mutations [
10‐
14] which could facilitate the tumor progression reducing the overall survival at long-term.
CD133 is widely recognized as a stem cell biomarker in normal and cancer colon tissue [
45‐
47]. Its expression was detected in around half of a series of precancerous colon adenomas [
48] and was found to be pronounced in invasive margins of colorectal tumors [
29]. Other authors reported that CD133 expression is not restricted to intestinal stem or cancer-initiating cells and that both CD133-positive and CD133-negative cells can initiate a tumor [
47]. In the present study, the high percentage of CD133 expression was correlated with shorter DFS but not with OS, tumor stage, or differentiation grade in CRC patients
, suggesting that this molecule may be relevant to determine recurrence. These findings are consistent with the study by Coco
et al. [
49], who found a higher risk of recurrence and death in CRC patients with increased CD133 levels. Reggiani
et al. [
50] concluded that CD133 is useful for the prognosis in stage I CRC patients and for the selection of patients requiring adjuvant treatment. Moreover, Jao
et al. [
51] correlated cytoplasmic CD133 expression with tumor local recurrence and survival in CRC patients. However, a similar study found no correlation between cytoplasmic CD133 and patient survival [
52], while Kojima
et al. [
53] observed no differences in DFS between CD133-positive and-negative patients, although they considered CD133 overexpression to be a risk factor in patients with well- and moderately-differentiated adenocarcinomas. CD133 expression on cell debris and the endoluminal surface has also been proposed as CRC biomarker. Horst
et al. [
29] found a significant correlation between endoluminal surface CD133 expression and low survival in CRC patients, while Xi
et al. [
54] reported that CD133 expression in membrane and cytoplasm of cells on the luminal surface of cancerous glands was of prognostic value in CRC patients. All these results are supported by CD133 mRNA studies too. Saigusa
et al. [
55] observed correlation between CD133 mRNA expression and survival and distant recurrence in rectal patients. Further, Kawamoto
et al. [
56] associated recurrence and short DFS with higher CD133 RNAm levels. Similar results observed Yasuda
et al. [
57].
The comparison of results among studies is hampered by methodological differences. Thus, CD133 staining patterns were found to differ in CRC between the use of AC133 (Miltenyi Biotech) and Ab19898 (Abcam) monoclonal antibodies [
49] and among the application of anti-CD133 (Cell Signalling), AC133 (Miltenyi Biotech), and polyclonal anti-CD133 (Santa Cruz Biotechnology) antibodies [
29]. These staining variations were confirmed in previous glioblastoma studies [
58]. In addition, whereas some authors compared cell cytoplasm staining between patients with less and more than 5% CD133 positive cells [
49,
54,
59], others compared the number of CD133-stained glands between patients with less and more than 50% positive glands [
29].
Finally, MGMT expression or methylation status has been related to radio-chemo/resistance in the CSC population in some tumors such as glioma [
24‐
26]. He
et al. [
25] reported that patients with methylated MGMT promoter and high CD133 expression had the worst progression-free survival. In contrast, Metellus
et al. [
26] observed shorter OS and progression-free survival in patients with unmethylated MGMT and high CD133 expression. In the present study, no significant association was found between MGMT and CD133 in CRC patients. However, consistent with the findings of He
et al. [
25], DFS and OS outcomes were worse in patients with low MGMT expression intensity and ≥50% CD133 expression.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Conceived and designed the experiments: CM, JP, RO. Performed the experiments: JAO, RO, CM. Analyzed the data: JAO, RO, CM, PJA, JGM. Wrote the paper: JAO, CM, JP. All authors read and approved the final manusript.